Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (11c)abt-627
2. 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic Acid
3. A 127722
4. A 127722.5
5. A 147627
6. A-127722
7. A-127722.5
8. A-147627
9. A127722
10. A127722.5
11. A147627
12. Abt 627
13. Abt-627
14. Abt627
15. Atrasentan
16. Xinlay
1. 195733-43-8
2. Atrasentan Hcl
3. Atrasentan (hydrochloride)
4. Atrasentan Hydrochloride [usan]
5. Abbot-147627
6. E4g31x93za
7. 3-pyrrolidinecarboxylicacid,4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-,hydrochloride (1:1), (2r,3r,4s)-
8. 195733-43-8 (hcl)
9. A-147627.1
10. Atrasentan Hydrochloride (usan)
11. Abbott 147627
12. Unii-e4g31x93za
13. (2r,3r,4s)-1-((dibutylcarbamoyl)methyl)-2-(p-methoxyphenyl)-4-(3,4-(methylenedioxy)phenyl)-3-pyrrolidinecarboxylic Acid, Monohydrochloride
14. (2r,3r,4s)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic Acid Hydrochloride
15. (2r,3r,4s)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic Acid Hydrochloride.
16. A 147627.1
17. D03009
18. (2r,3r,4s)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic Acid Hydrochloride
19. Chembl2106068
20. Dtxsid20173240
21. Ex-a4175
22. Atrasentan Hydrochloride [mi]
23. Hy-15403a
24. Mfcd13194884
25. Cs-1373
26. Atrasentan Hydrochloride [mart.]
27. Atrasentan Hydrochloride [who-dd]
28. Bs-16407
29. Atrasentan Hydrochloride, >=98% (hplc)
30. D82853
31. 733a438
32. A930316
33. Abt-627;abt627;abt 627;abbott 147627
34. Q27276859
35. (2r,3r,4s)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(n,n-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic Acid Hydrochloride Salt
36. (2r,3r,4s)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic Acid;hydrochloride
37. (2r,3r,4s)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylicacidhydrochloride
38. 3-pyrrolidinecarboxylic Acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, Monohydrochloride, (2r,3r,4s)-
39. 3-pyrrolidinecarboxylic Acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, Monohydrochloride, (2r-(2.alpha.,3.beta.,4.alpha.))
40. 3-pyrrolidinecarboxylic Acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, Monohydrochloride, (2r-(2alpha,3beta,4alpha))
| Molecular Weight | 547.1 g/mol |
|---|---|
| Molecular Formula | C29H39ClN2O6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 12 |
| Exact Mass | 546.2496647 g/mol |
| Monoisotopic Mass | 546.2496647 g/mol |
| Topological Polar Surface Area | 88.5 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 734 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Treatment of nephropathy
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Endothelin A Receptor Antagonists
Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN A RECECPTORS. (See all compounds classified as Endothelin A Receptor Antagonists.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Atrasentan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Atrasentan, including repackagers and relabelers. The FDA regulates Atrasentan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Atrasentan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Atrasentan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Atrasentan supplier is an individual or a company that provides Atrasentan active pharmaceutical ingredient (API) or Atrasentan finished formulations upon request. The Atrasentan suppliers may include Atrasentan API manufacturers, exporters, distributors and traders.
click here to find a list of Atrasentan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Atrasentan DMF (Drug Master File) is a document detailing the whole manufacturing process of Atrasentan active pharmaceutical ingredient (API) in detail. Different forms of Atrasentan DMFs exist exist since differing nations have different regulations, such as Atrasentan USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Atrasentan DMF submitted to regulatory agencies in the US is known as a USDMF. Atrasentan USDMF includes data on Atrasentan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Atrasentan USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Atrasentan suppliers with USDMF on PharmaCompass.
Atrasentan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Atrasentan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Atrasentan GMP manufacturer or Atrasentan GMP API supplier for your needs.
A Atrasentan CoA (Certificate of Analysis) is a formal document that attests to Atrasentan's compliance with Atrasentan specifications and serves as a tool for batch-level quality control.
Atrasentan CoA mostly includes findings from lab analyses of a specific batch. For each Atrasentan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Atrasentan may be tested according to a variety of international standards, such as European Pharmacopoeia (Atrasentan EP), Atrasentan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Atrasentan USP).
LOOKING FOR A SUPPLIER?
